The Global Immuno-oncology Therapeutics Market—Adoptive T-cell Therapies, Forecast to 2022

The Next Generation of Cancer Therapies

USD 3,000.00

* Required Fields

USD 3,000.00

PAY BY INVOICE

Be the first to review this product

Immuno-oncology refers to drugs that are used to stimulate the human immune system to target the fight against cancer. The immune system is capable of recognizing and eliminating foreign substances, including tumor cells. Tumors have, however, been able to escape detection by the immune system. There are drugs that can empower the immune system cells to attack tumor cells. Natural Killer (NK) cells are the main cells involved in the natural immune response. Once an immune response is initiated, the immune response can be sustained through memory, called adaptive immunity. Cytotoxic T cells are the main cells involved with adaptive immunity. The anti-cancer activity of NK cells and cytotoxic T cells is done thro

Key Issues Addressed

  • What adoptive T-cell (CAR-T & TCR) therapies are in development and for what indications?
  • What products and indications will be launched in the next 7 years?
  • Who is investing in the development of adoptive T-cell therapies, at what phase, and at what level of deal funding?
  • What are some of the cost implications for adoptive T-cell therapies, especially when combined with other immuno-oncology therapies?
  • What are the challenges to development and commercialization of adoptive T-cell therapies?
  • What challenges do payors face related to the high cost of specialty therapeutics?

Table of Contents

1. Executive Summary to the Adoptive T-cell Therapeutics Market
Key Takeaway
Scope and Segmentation
Executive Summary—Market Snapshot
8 Big Market Themes for Immuno-oncology Therapies
Hematological Cancers Dominate the Pipeline
Game Changing Companies
Investors Pour in Significant Funds
Key 2017 Predictions—Adoptive T-cell Therapy Market
2. Disruptive Pipeline Analysis
Key Methodology
Adoptive T-cell Therapy Drug Classes
Timeline of Adoptive T-cell Product Evolution
Timeline of Adoptive Immuno-oncology Product Approvals
3. Competitive Landscape
Competitive Landscape—Target Segments
Competitive Landscape—Target Product Counts
Adoptive T-cell Therapy Segmentation
Competitive Landscape—CAR-T (Chimeric Antigen Receptor T-cells)
Competitive Landscape—CAR-T (Chimeric Antigen Receptor T-cells) CR
Competitive Landscape—T-cell Receptor (TCR) Segment
4. Product Dashboards of Leading Adoptive T-cell Therapies
CAR-T Product Dashboard
TCR Product Dashboard
5. Commercialization Analysis
Opportunities in this Market
Challenges for this Market
Potential Game Changing Immuno-oncology Therapies
Overall Environmental Impact Factors
Immuno-oncology Area Product Patent Expirations
6. Commercialization Analysis—Biomarkers
Antigen Targets
7. Commercialization Analysis—Cost Considerations
Opportunities in this Market—Escalating Drug Costs
Adoptive T-cell Therapy Payor Environment
J-Codes, Annual Costs and US Payors
Adoptive T-cell Therapies—On-Label Reimbursement Path
Reimbursement Pathway—Off-Label: Medicare
Reimbursement Pathway—Off-Label: Commercial Payors
A Snapshot of Global Drug Price Control Methods
Pitfalls to Avoid
8. Commercialization Analysis—Key Companies and Products to Watch
Companies to Watch
Adoptive T-cell Therapy Forecast—2022 ($3.9 Billion) Forecasts by Product
9. Commercialization Analysis—Funding Considerations
Immuno-oncology Milestones
Deal and Financing—Adoptive T-cell Therapies
10. Conclusion and Future Outlook
Key Conclusions
New Market Opportunities—Adoptive T-cell Therapies
The Last Word—3 Big Predictions
Legal Disclaimer
11. Appendix—CAR-T Therapies Development Pipeline Summaries
Pipeline Analysis—CAR-T Segment, Products in Development
12. Appendix—T-cell Receptor Therapies: Development Pipeline Summary
Pipeline Analysis—T-cell Receptor Segment, Products in Development
List of Exhibits
13. The Frost & Sullivan Story

Infographic



List of Figures & Charts

1. Immuno-oncology Therapies Market: Competitive Landscape—Count of Marketed and Pipeline Products by Type Group and Phase, Global, 2017
2. Immuno-oncology Therapies Market: Competitive Landscape—Count of Marketed and Pipeline Products by Type and Phase, Global, 2017
3. Immuno-oncology Therapeutics Market: Timeline of New Indication Approvals, Global, 2014–2020
4. Oncology Drug Compendia Recognized by Payors, US, 2017
5. Adoptive T-cell Therapeutics: Market Developments, Global, 2017
6. Adoptive T-cell Therapeutics: Market Developments, Global, 2016–2017
7. Adoptive T-cell Therapies Market: CAR-T and TCR Segments—Deals and Financing, Global, 2017
8. Adoptive T-cell Therapies Market: CAR-T and TCR Segments—Deals and Financing, Global, 2016
9. Adoptive T-cell Therapies Market: CAR-T and TCR Segments—Deals and Financing, Global, 2015
10. Adoptive T-cell Therapies Market: CAR-T and TCR Segments—Deals and Financing, Global, 2014–2015
11. Adoptive T-cell Therapies Market: CAR-T and TCR Segments—Deals and Financing, Global, 2014
12. Adoptive T-cell Therapies Market: CAR-T and TCR Segments—Deals and Financing, Global, 2013
13. Adoptive T-cell Therapies Market: CAR-T and TCR Segments—Deals and Financing, Global, 2012
14. CAR-T Therapeutics Segment: Products in Development, Global, 2017
15. T-cell Receptor Therapeutics Segment: Products in Development, Global, 2017


1. Immuno-oncology Therapeutics Market: Market Snapshot, Global, 2017–2022
2. Adoptive T-cell Therapies Market: Disease Segments, Global, 2017
3. Immuno-oncology Drug Market: Adoption Share by Region, Global, 2015
4. Immuno-oncology Market: Revenue Forecast Scenario Analysis, Global, 2015–2020
5. Percent Pipeline, 2017
6. Pipeline Products, Percent Breakdown, 2017
7. Adoptive T-cell Therapies Market: Disease Segments, Global, 2017
8. Adoptive T-cell Therapies Market: Companies, Global, 2017
9. Adoptive T-cell Therapies Market: Alliance Funding, Global, 2017
10. Adoptive T-cell Therapy Market: Key Predictions, Global, 2017
11. Adoptive T-cell Therapies Market: Drug Classes, Global, 2017
12. Adoptive T-cell Therapies Market: CAR-T and TCR Development, Global, 1950–2020
13. Immuno-oncology Therapeutics Market: Timeline of New Product Approvals, Global, 2011–2017
14. Adoptive T-cell Therapies Market: Drug Class, Global, 2017
15. CAR-T Therapeutics Segment: Competitive Landscape—Pipeline Products, Global, 2017
16. CAR-T Therapeutics Market: Competitive Landscape—Pipeline Products, Global, 2017
17. T-cell Receptor Therapeutics Segment: Competitive Landscape—Pipeline Products, Global, 2017
18. CAR-T Immunotherapy: Product Dashboard—Tisagenlecleucel-T, Global, 2017
19. CAR-T Immunotherapy: Product Dashboard—Axicabtagene, Global, 2017
20. TCR Immunotherapy: Product Dashboard—NY-ESO-1 T-cell Therapy, Global, 2017
21. Adoptive T-cell Therapies Market: Opportunities, Global, 2017
22. Adoptive T-cell Therapies Market: Challenges, Global, 2017
23. Adoptive T-cell Therapies Market: Impact Factors, Global, 2017
24. Immuno-oncology Therapeutics Market: Patent Expirations, Global, 2020–2030
25. Adoptive T-cell Therapy Market: Targets and Process, Global, 2017
26. Adoptive T-cell Therapy Market: Game-changing Strategies, Global, 2017
27. Adoptive T-cell Therapies Market: Segmentation, Global, 2017
28. Immuno-oncology Therapeutics Market: Drug Payor Ecosystem, Global, 2017
29. Adoptive T-cell Therapeutics Market: Reimbursement Ecosystem, Global, 2017
30. Adoptive T-cell Therapies Market: Target Forecasts by Product, Global, 2017
31. Adoptive T-cell Therapy Market: Key Conclusions and Future Outlook, Global, 2017



Keyword1

Keyword2

Keyword3

Related Research

Release Date : 09-Jan-18

Region : North America

Release Date : 03-Jan-18

Region : North America

Release Date : 29-Dec-17

Region : North America

Release Date : 28-Dec-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.